Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Bupropion sustained release: side effect profile

¹Department of Psychiatry, West Virginia University, Charleston, USA.

The Journal of Clinical Psychiatry

|April 29, 1998

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.

The Journal of clinical psychiatry·2000

Same author

Safety profile of sustained-release bupropion in depression: results of three clinical trials.

Clinical therapeutics·1999

Same author

Antidepressant drugs: disturbing and potentially dangerous adverse effects.

The Journal of clinical psychiatry·1998

Same author

Valproic acid-associated encephalopathy with coma.

The American journal of psychiatry·1995

Same author

Akathisia and sertraline.

The Journal of clinical psychiatry·1993

Same author

Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.

The Journal of clinical psychiatry·1992

Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026

Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026

Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026

Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026

Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026

Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026

See all related articles

Bupropion sustained-release (SR) offers comparable antidepressant efficacy to immediate-release (IR) formulations with fewer side effects. This bupropion SR formulation also shows a substantially lower incidence of seizures compared to high-dose IR bupropion.

Area of Science:

Pharmacology
Neuroscience
Clinical Psychiatry

Background:

Bupropion immediate-release (IR) has been an established antidepressant since 1988.
A sustained-release (SR) formulation of bupropion was approved in 1996.

Purpose of the Study:

To compare the efficacy and side effect profile of bupropion SR with bupropion IR.
To evaluate the safety and tolerability of bupropion SR in antidepressant therapy.

Main Methods:

Comparative analysis of clinical trial data for bupropion IR and SR formulations.
Review of efficacy and adverse event data, including seizure incidence.

Main Results:

Bupropion SR demonstrates similar antidepressant efficacy to bupropion IR.

Related Experiment Videos

Bupropion SR exhibits a comparable, and in some aspects reduced, side effect profile compared to IR.

Seizure incidence is substantially lower with bupropion SR than with high-dose IR.

Conclusions:

Bupropion SR is an effective antidepressant with a favorable safety profile.
The SR formulation offers advantages over IR, particularly regarding side effects and seizure risk.
Bupropion SR presents a viable alternative to other newer antidepressants, with minimal sexual side effects and drug interactions.